Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAG-Tn3 + AS15 Vaccine in High-Risk HER2-Negative Breast Cancer
NCT02364492Phase 1Completed
- Sponsor
- Institut Pasteur
- Start
- Feb 2015
- Primary completion
- Oct 2019
- Modality
- Cyclic Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MAG-Tn3 in breast cancer, sponsored by Institut Pasteur. Primary endpoint: Dose-Limiting Toxicities. Started Feb 2015; status: completed.
02
Drugs
MAG-Tn3
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02364492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364492.